These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Progression of intestinal permeability changes and alpha-synuclein expression in a mouse model of Parkinson's disease. Kelly LP; Carvey PM; Keshavarzian A; Shannon KM; Shaikh M; Bakay RA; Kordower JH Mov Disord; 2014 Jul; 29(8):999-1009. PubMed ID: 24898698 [TBL] [Abstract][Full Text] [Related]
28. Unravelling the role of gut microbiota in Parkinson's disease progression: Pathogenic and therapeutic implications. Rani L; Mondal AC Neurosci Res; 2021 Jul; 168():100-112. PubMed ID: 33417973 [TBL] [Abstract][Full Text] [Related]
29. Potentials of autophagy enhancing natural products in the treatment of Parkinson disease. Olubodun-Obadun TG; Ishola IO; Adeyemi OO Drug Metab Pers Ther; 2021 Aug; 37(2):99-110. PubMed ID: 35737301 [TBL] [Abstract][Full Text] [Related]
30. α-Synuclein pathology in Parkinson's disease and related α-synucleinopathies. Henderson MX; Trojanowski JQ; Lee VM Neurosci Lett; 2019 Sep; 709():134316. PubMed ID: 31170426 [TBL] [Abstract][Full Text] [Related]
31. Increased urinary indoxyl sulfate (indican): new insights into gut dysbiosis in Parkinson's disease. Cassani E; Barichella M; Cancello R; Cavanna F; Iorio L; Cereda E; Bolliri C; Zampella Maria P; Bianchi F; Cestaro B; Pezzoli G Parkinsonism Relat Disord; 2015 Apr; 21(4):389-93. PubMed ID: 25707302 [TBL] [Abstract][Full Text] [Related]
32. Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome. Hill-Burns EM; Debelius JW; Morton JT; Wissemann WT; Lewis MR; Wallen ZD; Peddada SD; Factor SA; Molho E; Zabetian CP; Knight R; Payami H Mov Disord; 2017 May; 32(5):739-749. PubMed ID: 28195358 [TBL] [Abstract][Full Text] [Related]
33. Rethinking Parkinson Disease: Exploring Gut-Brain Interactions and the Potential Role of Exercise. Zapanta K; Schroeder ET; Fisher BE Phys Ther; 2022 May; 102(5):. PubMed ID: 35225349 [TBL] [Abstract][Full Text] [Related]
34. Parkinson's disease and the gut: Models of an emerging relationship. Bindas AJ; Kulkarni S; Koppes RA; Koppes AN Acta Biomater; 2021 Sep; 132():325-344. PubMed ID: 33857691 [TBL] [Abstract][Full Text] [Related]
35. Microbiome-Gut-Brain Axis and Toll-Like Receptors in Parkinson's Disease. Caputi V; Giron MC Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29882798 [TBL] [Abstract][Full Text] [Related]
36. The Link between Gut Dysbiosis and Neuroinflammation in Parkinson's Disease. Baizabal-Carvallo JF; Alonso-Juarez M Neuroscience; 2020 Apr; 432():160-173. PubMed ID: 32112917 [TBL] [Abstract][Full Text] [Related]
37. The microbiome-gut-brain axis in Parkinson disease - from basic research to the clinic. Tan AH; Lim SY; Lang AE Nat Rev Neurol; 2022 Aug; 18(8):476-495. PubMed ID: 35750883 [TBL] [Abstract][Full Text] [Related]
38. Exploring the multifactorial aspects of Gut Microbiome in Parkinson's Disease. Pavan S; Prabhu AN; Prasad Gorthi S; Das B; Mutreja A; Shetty V; Ramamurthy T; Ballal M Folia Microbiol (Praha); 2022 Oct; 67(5):693-706. PubMed ID: 35583791 [TBL] [Abstract][Full Text] [Related]
39. Small Intestinal Bacterial Overgrowth as Potential Therapeutic Target in Parkinson's Disease. Dănău A; Dumitrescu L; Lefter A; Tulbă D; Popescu BO Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769091 [TBL] [Abstract][Full Text] [Related]
40. Iron Dysregulation and Inflammagens Related to Oral and Gut Health Are Central to the Development of Parkinson's Disease. Vuuren MJV; Nell TA; Carr JA; Kell DB; Pretorius E Biomolecules; 2020 Dec; 11(1):. PubMed ID: 33383805 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]